Novartis : Listing de Sandoz autour du 4 octobre
>Effets bénéfiques du spin-off pour Novartis - Dans une volonté de recentrage sur son core business de médecine innovante, Novartis prévoit de se séparer de sa filiale Sandoz (activité générique) au travers d’une opération de spin-off autour du 4 octobre 2023. Pour rappel, cette activité correspond à 18% des ventes du groupe et 11% de son Core EBIT 2022. Nous considérons qu’une telle opération aura des effets bénéfiques immédiats : groupe plus lisible, plus facile à g...Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.